We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+44.61%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$46.6M
Cap. Flow
-$131M
Cap. Flow %
-26.01%
Top 10 Hldgs %
39.38%
Holding
180
New
41
Increased
13
Reduced
50
Closed
76

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.2M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.73M
4
SAGE
Sage Therapeutics
SAGE
+$6.1M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.3M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$12.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.1M
4
UTHR icon
United Therapeutics
UTHR
+$9.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 39.26%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
1
PUT
Relmada Therapeutics
RLMD
$546M
$28.7M 5.72%
775,300
+493,000
+175% +$13.7M
RLMD icon
2
CALL
Relmada Therapeutics
RLMD
$546M
$28.7M 5.72%
775,300
+475,300
+158% +$13.2M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$777B
$21.4M 4.27%
+60,000
New +$23.8M
SGEN
4
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$20.5M 4.09%
+150,000
New +$24.4M
BIIB icon
5
CALL
Biogen
BIIB
$29.6B
$18.8M 3.75%
70,500
-41,700
-37% -$8.86M
AXSM icon
6
PUT
Axsome Therapeutics
AXSM
$12.4B
$18.2M 3.62%
407,600
-92,400
-18% -$4.62M
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.6M 3.5%
978,783
+929,684
+1,893% +$12.2M
DICE
8
CALL
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$15.2M 3.03%
+748,900
New +$13.6M
ESPR
9
DELISTED
Esperion Therapeutics
ESPR
$14.3M 2.85%
2,131,147
+76,545
+4% +$526K
BIIB icon
10
PUT
Biogen
BIIB
$29.6B
$14.2M 2.83%
+53,200
New +$11.3M
RXDX
11
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$13.6M 2.72%
+231,181
New +$10.6M
XBI icon
12
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$11.9M 2.37%
150,000
-200,000
-57% -$16.9M
ALT icon
13
CALL
Altimmune
ALT
$552M
$10.8M 2.14%
842,600
+539,000
+178% +$7.96M
RXDX
14
CALL
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$10.5M 2.09%
+178,000
New +$8.14M
DICE
15
PUT
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$10.2M 2.04%
+504,100
New +$9.18M
SRPT icon
16
CALL
Sarepta Therapeutics
SRPT
$1.68B
$9.42M 1.88%
85,200
-14,800
-15% -$1.49M
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$9.11M 1.81%
+492,275
New +$7.73M
BLU
18
DELISTED
BELLUS Health Inc.
BLU
$8.98M 1.79%
850,134
-168,193
-17% -$1.79M
CLDX icon
19
Celldex Therapeutics
CLDX
$2.78B
$8.92M 1.78%
317,476
-220,482
-41% -$6.76M
MIST icon
20
Milestone Pharmaceuticals
MIST
$149M
$7.86M 1.57%
855,616
-523,806
-38% -$3.97M
ISEE
21
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.86M 1.57%
437,900
+193,500
+79% +$2.54M
TCDA
22
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
$7.63M 1.52%
727,900
+635,000
+684% +$6.94M
GOSS icon
23
Gossamer Bio
GOSS
$69.7M
$7.31M 1.46%
610,407
-389,980
-39% -$4.84M
AMLX icon
24
CALL
Amylyx Pharmaceuticals
AMLX
$1.96B
$7.04M 1.4%
250,000
-100,800
-29% -$2.51M
KRYS icon
25
PUT
Krystal Biotech
KRYS
$9.65B
$6.63M 1.32%
+95,200
New +$6.88M
1
2 3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ikarian Capital held 180 positions worth $502M, down 8.5% from $548M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital withdrew a net $131M in Q3 2022, closing 76 positions and reducing 50 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Prometheus Biosciences, Inc. Common Stock worth $13.6M.

  • Ikarian Capital's largest Q3 2022 buy was Prometheus Biosciences, Inc. Common Stock: 231,181 shares worth $13.6M.
  • Ikarian Capital added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.2M increase.
  • Ikarian Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $11.1M.
  • Ikarian Capital fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $12.7M.
  • Ikarian Capital's ten largest holdings make up 39% of its $502M portfolio in Q3 2022.
  • Ikarian Capital opened 41 new positions and closed 76 in Q3 2022.
  • Ikarian Capital's portfolio value fell 8.5% quarter-over-quarter to $502M.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.